Nussbaum, Harvey E.; Leff, William; Mattia, Virginius D.; Hillman, Ernest
April 1957
Angiology;Apr1957, Vol. 8 Issue 2, p198
Academic Journal
The results of this preliminary study indicate that iproniazid phosphate is worthy of further clinical and laboratory trial to determine its value, if any, in the treatment of hypertension. Although its hypotensive effect is not as marked as that of various ganglionic-blocking agents, it nevertheless has demonstrated effectiveness in more than half the patients observed. Whether this effect is temporary or not is impossible to determine in a study of such short duration. Side effects of iproniazid may be severe and incapacitating, but at the dosages employed in this study, no therapeutic problems developed. Dosages beyond 150 mg/day should only be administered to patients who can be carefully observed since this appears to be the critical level for development of serious side effects. Although it is premature to recommend iproniazid for the treatment of hypertension, early results have been encouraging enough to warrant continued study of this drug singly and in combination with other hypotensive agents. Marked subjective improvement in almost all patients coupled with limited objective improvement in the majority indicates a need for further investigations of not only iproniazid, but related amine oxidase inhibitors.


Related Articles

  • Hypertension in Infantile Polycystic Renal Disease. Rahill, W. Joseph; Rubin, Mitchell I. // Clinical Pediatrics;Apr1972, Vol. 11 Issue 4, p232 

    Two infants with polycystic renal disease and severe hypertension had studies of renal function and antihypertensive therapy. One infant with adequate renal function died with uncontrolled hypertenson. The second infant's blood pressure approached normal; now three and one-half years of age, he...

  • The Effect of How Outcomes Are Framed on Decisions about Whether to Take Antihypertensive Medication: A Randomized Trial. Carling, Cheryl L. L.; Kristoffersen, Doris Tove; Oxman, Andrew D.; Flottorp, Signe; Fretheim, Atle; Schünemann, Holger J.; Akl, Elie A.; Herrin, Jeph; MacKenzie, Thomas D.; Montori, Victor M. // PLoS ONE;2010, Vol. 5 Issue 3, p1 

    Background: We conducted an Internet-based randomized trial comparing three valence framing presentations of the benefits of antihypertensive medication in preventing cardiovascular disease (CVD) for people with newly diagnosed hypertension to determine which framing presentation resulted in...

  • Drug management of hypertension in primary care. Hall, Gwen // Primary Health Care;Apr2006, Vol. 16 Issue 3, p27 

    The article reports on the drug management of hypertension in primary care in Great Britain. This condition continues to pose clinical and financial burdens on the National Health Service (NHS). The General Medical Services (GMS) contract offers incentives for improving the detection and control...

  • Blood pressure management. Fallon, Noeleen // World of Irish Nursing & Midwifery;Apr2006, Vol. 14 Issue 4, p35 

    The article focuses on blood pressure management. It defines blood pressure as the pressure exerted within the blood vessel walls as the heart pumps and circulates the blood around the body. It defines hypertension as the level of blood pressure above which intervention has been shown to reduce...

  • Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients. Odili, Augustine N; Ezeala-Adikaibe, Birinus; Ndiaye, Mouhamadou B; Anisiuba, Benedict C; Kamdem, Marius M; Ijoma, Chinwuba K; Kaptue, Joseph; Boombhi, Hilaire J; Kolo, Philip M; Shu, Elvis N; Thijs, Lutgarde; Stassen, Jan A; Omotoso, Babatunde A; Kingue, Samuel; Ba, Serigne A; Lemogoum, Daniel; M'Buyamba-Kabangu, Jean-René; Ulasi, Ifeoma I // Trials;2012, Vol. 13 Issue 1, p59 

    Background: The epidemic surge in hypertension in sub-Saharan Africa is not matched by clinical trials of antihypertensive agents in Black patients recruited in this area of the world. We mounted the Newer versus Older Antihypertensive agents in African Hypertensive patients (NOAAH) trial to...

  • Impact of Increased Heart Rate on Clinical Outcomes in Hypertension: Implications for Antihypertensive Drug Therapy. Palatini, Paolo; Benetos, Athanase; Julius, Stevo // Drugs;2006, Vol. 66 Issue 2, p133 

    Thirty-eight studies have been published to date on the association between elevated heart rate and mortality. After adjustment for other risk factors, only two studies for all-cause mortality and four studies for cardiovascular mortality reported an absence of association between heart rate and...

  • NICE signals significant changes in BP guidance.  // Pulse;11/5/2005, Vol. 65 Issue 43, p4 

    Reports on the study which found that the ASCOT trial is likely to have a significant impact on new NICE and British Hypertension Society guidelines for hypertension in Great Britain. Confirmation of the need for a wider evaluation of hypertension guidance; Improvement of the first-line therapy;...

  • ACE Inhibitors vs. Calcium Antagonists in Reducing Stroke. Walling, Anne D. // American Family Physician;6/15/2001, Vol. 63 Issue 12, p2458 

    Presents information on a study by the international Blood Pressure Lowering Treatment Trialists' Collaboration to estimate the benefits of angiotensin-converting enxyme (ACE) inhibitors and other medications for the reduction of stroke. Description of the study and its results; Conclusion that...

  • Review: Low-dose diuretics are the best first-line antihypertensive therapy.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p3 

    This article focuses on a study related to health outcomes associated with various antihypertensive therapies used as first-line agents, published in the 2003 issue of "Journal of the American Medical Association." Two investigators independently extracted data on patients, interventions, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics